Stock analysts at Maxim Group initiated coverage on shares of Cancer Genetics (NASDAQ:CGIX) in a research report issued on Thursday. The brokerage set a “buy” rating and a $6.00 price target on the medical research company’s stock. Maxim Group’s target price points to a potential upside of 207.69% from the stock’s current price.
The analysts wrote, “As the paradigm in oncology shifts to immune therapy with CAR-T, PARPs, Checkpoints, and even BTK inhibitors attracting attention, we must not forget that it is the advances in diagnostics/theranostics and molecular profiling that enable guided therapy.””
A number of other equities analysts have also recently issued reports on CGIX. HC Wainwright set a $6.00 target price on Cancer Genetics and gave the stock a “buy” rating in a report on Tuesday, August 15th. ValuEngine cut Cancer Genetics from a “hold” rating to a “sell” rating in a report on Friday, September 1st. Finally, Zacks Investment Research cut Cancer Genetics from a “hold” rating to a “sell” rating in a report on Wednesday, October 4th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. Cancer Genetics has a consensus rating of “Hold” and a consensus price target of $5.56.
Several hedge funds have recently modified their holdings of the company. Vanguard Group Inc. increased its stake in shares of Cancer Genetics by 61.9% in the second quarter. Vanguard Group Inc. now owns 516,785 shares of the medical research company’s stock valued at $2,041,000 after buying an additional 197,619 shares during the period. Renaissance Technologies LLC increased its stake in shares of Cancer Genetics by 44.8% in the first quarter. Renaissance Technologies LLC now owns 449,600 shares of the medical research company’s stock valued at $1,843,000 after buying an additional 139,200 shares during the period. Granahan Investment Management Inc. MA increased its stake in shares of Cancer Genetics by 26.3% in the third quarter. Granahan Investment Management Inc. MA now owns 237,431 shares of the medical research company’s stock valued at $641,000 after buying an additional 49,371 shares during the period. Thompson Davis & CO. Inc. increased its stake in shares of Cancer Genetics by 5,465.0% in the second quarter. Thompson Davis & CO. Inc. now owns 111,300 shares of the medical research company’s stock valued at $440,000 after buying an additional 109,300 shares during the period. Finally, Northern Trust Corp increased its stake in shares of Cancer Genetics by 61.0% in the second quarter. Northern Trust Corp now owns 32,122 shares of the medical research company’s stock valued at $127,000 after buying an additional 12,168 shares during the period. 12.71% of the stock is owned by institutional investors.
TRADEMARK VIOLATION NOTICE: This report was originally published by Week Herald and is the sole property of of Week Herald. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://weekherald.com/2017/12/09/cancer-genetics-cgix-now-covered-by-maxim-group.html.
Cancer Genetics Company Profile
Cancer Genetics, Inc is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information.
Receive News & Ratings for Cancer Genetics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics Inc and related companies with MarketBeat.com's FREE daily email newsletter.